STATE ANXIETY ASSESSMENT IN PATIENTS WITH MYASTHENIA GRAVIS

Authors:

Abstract:

182 patients with myasthenia gravis aged 18 to 83 years were examined. Patients were assigned to the class and subclass of myasthenia gravis according to the Myasthenia Gravis Foundation of America, the severity of myasthenia gravis was quantified on the Quantitative Myasthenia Gravis score, and the level of state anxiety was determined on the Spielberger-Hanin test. An immunological test was performed to determine the presence and titer of antibodies to acetylcholine receptors, muscle‐specific receptor tyrosine kinase, and to determine the presence of antibodies against titin and SOX1. The mean level of state anxiety in patients with ocular form of disease was 44.0 (41.0; 48.0) points, which corresponds to a moderate level and does not require correction. The corresponding index in patients with generalized myasthenia gravis was significantly higher and amounted to 53.0 (45.0; 59.0) points (p <0.001), which corresponds to a high level of state anxiety and requires its correction. It was found that the state anxiety level correlates with the age of patients (p=0.19; p=0.008), clinical form of myasthenia gravis (p=-0.35; p=0.003), with indices of assessment of the myasthenia gravis severity (p=0.54; p<0.001), and with the titer of antibodies against acetylcholine receptors (p=0.46; p<0.001).

Keywords:

myasthenia gravis anxiety antibodies titin SOX1 muscle-specific kinase acetylcholine receptors

References:

1. Kalbus OI. Vyvchennia yakosti zhyttia ta tryvozhnosti u khvorykh na miasteniiu (kliniko-paraklinichne spivstavlennia). ScienceRise: Medical Science. 2018;3(23):10–13. doi: 10.15587/2519-4798.2018.127557. [in Ukrainian]
2. Kalbus OI. Otsinka yakosti zhyttia khvorykh na miasteniiu. ScienceRise: Medical Science. 2018;2(22):24–27. doi: 10.15587/2519-4798.2018.124132. [in Ukrainian]
3. Raygorodskiy DYa, editor. Prakticheskaya psikhodiagnostika. Metodiki i testy: uchebnoye posobiye. Samara: BAKHRAKH-M; 2001. 672 s. [in Russian]
4. Alekseeva T, Kreis O, Gavrilov Y, Valko P, Weber K, Valko Y. Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis. Journal of Neurology. 2019;266(8):2027–2034. doi: 10.1007/s00415-019-09374-1
5. Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta neurologica Scandinavica. Supplementum. 2014;198:26–31. doi: 10.1111/ane.12233
6. Aysal F, Karamustafalioğlu O, Özçelik B, Yilmaz M, Karamustafalioğlu N, Yumrukçal H, et al. The Relationship of Symptoms of Anxiety and Depression with Disease Severity and Treatment Modality in Myasthenia Gravis: A Cross-sectional Study. Noro Psikiyatr Ars. 2013 Dec;50(4):295–300. doi: 10.4274/npa.y5611
7. Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience. 2015;22(7):1164–1169. doi: 10.1016/j.jocn.2015.01.022
8. Boldingh M, Dekker L, Maniaol A, Brunborg C, Lipka A, Niks E et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health and Quality of Life Outcomes. 2015;13(1). doi: 10.1186/s12955-015-0298-1
9. Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders. 2016;26(1)41–46. doi: 10.1016/j.nmd.2015.10.009.
10. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16–23. doi: 10.1212/wnl.55.1.16
11. Oliveira E, Nacif S, Urbano J, Silva A, Oliveira C, Perez E et al. Sleep, lung function, and quality of life in patients with myasthenia gravis: A cross-sectional study. Neuromuscular Disorders. 2017;27(2):120–127. doi: 10.1016/j.nmd.2016.11.015
12. Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open. 2011;1(2):e000313–e000313. doi: 10.1136/bmjopen-2011-000313
13. Yamamoto A, Kimura T, Watanabe S, Yoshikawa H. Clinical characteristics of patients with myasthenia gravis accompanied by psychiatric disorders. Neurology and Clinical Neuroscience. 2019;7(2):65–70. doi: 10.1111/ncn3.12267
14. Yang Y, Zhang M, Guo J, Ma S, Fan L, Wang X et al. Quality of life in 188 patients with myasthenia gravis in China. International Journal of Neuroscience. 2016;126(5):455–462. doi: 10.3109/00207454.2015.1038712
15. Ybarra M, Kummer A, Frota E, Oliveira J, Gomez R, Teixeira A. Psychiatric disorders in myasthenia gravis. Arquivos de Neuro-Psiquiatria. 2011; 69(2a):176–179. Doi: 10.1590/S0004-282X2011000200006

Publication:

«World of Medicine and Biology» Vol. 17 No. 76 (2021) , с. 48-52
УДК 616.74+616.8]-009.17-038.8

DOI:

https://doi.org/10.26724/2079-8334-2021-2-76-48-52